Follow us on


At SMS-oncology we believe that oncology trials require oncology experts. With a focus and dedication to oncology and hemato-oncology, the combined experience of SMS-oncology staff covers a wide variety of anti-cancer drugs in a broad range of tumor types covering all development phases. We are specialized in early phase and immune-oncology trials.

Since the founding of SMS-oncology, we have acquired a vast amount of experience in the oncology arena, which can be summarized into:


From small biotech to big pharmaceutical companies, of which many return for continuing collaboration


Clinical operations

Phase I to IV oncology studies (full-service or stand-alone services) throughout Europe and US



Expert advice regarding the clinical development of oncology compounds to sponsors


Wide range of
indications &
drug modalities

From solid tumors to hemato-oncology indications & innovative therapies to generics

Clinical operations

Beyond our specialization in early phase (phase I and I/II) trials, SMS-oncology is experienced in conducting late phase trials, pivotal trials and post-marketing trials:










*Other involves for example data management activities at sites


SMS-oncology has provided expert advice underpinning our clients’ oncology drug development path, which currently can be summarized as:






Tumor indications

Below is a list of tumor types we have conducted clinical trials in:

Solid tumors:

  • Bladder cancer
  • Breast cancer
  • Brain tumors (incl. Glioblastoma)
  • Cervical cancer
  • Colorectal cancer
  • Head and neck cancer
  • Kidney cancer
  • Liver cancer
  • Lung cancer (incl. NSCLC)
  • Melanoma
  • PNET/Neuroendocrine tumors
  • Ovarian cancer
  • Pancreas cancer
  • Prostate cancer
  • Sarcoma
  • All comer trials (various solid tumors)


  • Acute Myeloid Leukemia (AML)
  • Acute Lymphocytic Leukemia (ALL)
  • Chronic Myeloid Leukemia (CML)
  • Chronic Lymphoid Leukemia (CLL)
  • Hematologic malignancies
  • Multiple Myeloma

Anticancer drug modalities

Below is a list of modalities SMS-oncology has experience with:

Chemotherapy (related):

  • e.g. anthracyclines, liposomal platinum compound, taxanes
  • chemotherapy conjugates (e.g. nanoparticle-based)

Small molecules:

  • HDAC inhibitors
  • Angiogenesis inhibitors (e.g. anti-VEGF)
  • Integrin receptor antagonists
  • Tyrosine kinase inhibitors (TKIs)
  • Cell cycle inhibitors

Hormonal therapies:

  • Hormone-receptor targeted therapies
  • Aromatase inhibitors

Biological therapies:

  • Gene therapies
  • Immuno-modulators (including antibodies and peptides)
  • Non-specific immune stimulators
  • Immune checkpoint inhibitors
  • Adoptive cell transfer of autologous cancer-specific T cells
  • Vaccines
  • Monoclonal antibodies
  • Antibody drug conjugates
  • Oncolytic viruses


  • Liposomal corticosteroids
  • Nutraceuticals
  • Oligonucleotides (e.g. miRNA-based molecules)
  • Peptides & radiolabeled proteins
Request for proposal
Subscribe to our oncology feed
Contact us